External Validation of the 2003 Leibovich Prognostic Score in Patients Randomly Assigned to SORCE, an International Phase III Trial of Adjuvant Sorafenib in Renal Cell Cancer.
Bhavna OzaTim EisenEleni FrangouGrant D StewartAxel BexAlastair W S RitchieRichard S KaplanBenjamin SmithIan D DavisMartin R StocklerLaurence AlbigesBernard EscudierJames M G LarkinSteven JoniauBarry HancockGregers G HermannJoaquim BellmuntMahesh K B ParmarPatrick RoystonAngela Mary MeadePublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
The 2003 Leibovich score discriminates between intermediate-risk and high-risk clear-cell and non-clear-cell RCC groups in contemporary data, supporting its use for risk stratification in adjuvant clinical trials. Over time, metastasis-free survival for patients with locally advanced RCC has improved. Contemporary data from adjuvant RCC trials should be used to improve prognostication for patients with RCC.
Keyphrases
- phase iii
- clear cell
- clinical trial
- renal cell carcinoma
- free survival
- early stage
- open label
- phase ii
- locally advanced
- electronic health record
- end stage renal disease
- ejection fraction
- squamous cell carcinoma
- double blind
- prognostic factors
- rectal cancer
- single cell
- papillary thyroid
- cell therapy
- randomized controlled trial
- radiation therapy
- study protocol
- phase ii study
- patient reported outcomes
- mesenchymal stem cells
- machine learning
- artificial intelligence